As part of its UMBRELLA study, numares HEALTH has discovered a urinalysis procedure for diagnosing the impending rejection of a transplanted kidney. By the end of 2016, the Regensburg-based company aims to have a marketable product that will significantly improve post-transplant care. This product will be the world’s first NMR-based method of in-vitro diagnosis for renal conditions.
